Acute myeloid leukemia (AML) is the most common acute leukemia in adults that affects the
myeloid lineage. The recent advances have upgraded our understanding of the cytogenetic …

Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy in terms of
clinical features, underlying pathogenesis and treatment outcomes. Recent advances in …

The studies concerning clinical implications of TET2 mutation in patients with primary acute
myeloid leukemia (AML) are scarce. We analyzed TET2 mutation in 486 adult patients with …

DNMT3A mutations are associated with poor prognosis in acute myeloid leukemia (AML),
but the stability of this mutation during the clinical course remains unclear. In the present …

After the discovery of NPM1-mutated acute myeloid leukemia (AML) in 2005 and its
subsequent inclusion as a provisional entity in the 2008 World Health Organization …

Mutations in the additional sex comb-like 1 (ASXL1) gene were recently shown in various
myeloid malignancies, but they have not been comprehensively investigated in acute …

The TP53 mutation is frequently detected in acute myeloid leukemia (AML) patients with
complex karyotype (CK), but the stability of this mutation during the clinical course remains …

Clinical outcome of patients with acute myeloid leukemia (AML) is associated with
demographic and genetic features. Although the associations of acquired genetic alterations …

The development of acute myeloid leukemia (AML) is a multistep process that requires at
least two genetic abnormalities for the development of the disease. The identification of …

Abstract Disease Overview: Acute myeloid leukemia (AML) results from accumulation of
abnormal immature cells in the marrow. These cells interfere with normal hematopoiesis can …